RxDoctor Payments Data

Michael Rave, MD

Cardiovascular Disease · Morehead City, NCNPI 1326011339

Payments from drug & device makers

$5,133in general payments, 2019–2025

Across 335 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$756
  • Merck$404
  • Johnson & Johnson$355
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$279
  • Pfizer$216
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,98697%
  • Education$1473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,133 in reported general payments places this provider in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$299,930
Medicare patients
1,667
Services billed
4,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban621$689,171
XareltoRivaroxaban174$178,681
EntrestoSacubitril/Valsartan165$162,921
FarxigaDapagliflozin Propanediol92$70,983
JardianceEmpagliflozin43$51,214
Repatha SureclickEvolocumab24$22,340
Praluent PenAlirocumab14$17,440
Metoprolol Succinate635$8,731
Dabigatran EtexilateDabigatran Etexilate Mesylate22$6,819
Dofetilide35$5,669
Atorvastatin Calcium434$5,330
Flecainide Acetate115$3,720
Ranolazine ErRanolazine53$3,700
Losartan Potassium341$3,363
Diltiazem 24hr Er (Cd)Diltiazem Hcl127$3,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$216$689,171621 claims
Johnson & JohnsonXarelto$355$178,681174 claims
NovartisEntresto$1,047$162,921165 claims
AstraZenecaFarxiga$79$70,98392 claims
Boehringer IngelheimJardiance$112$51,21443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Morehead City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →